HVTN 702

HVTN 702 was a clinical trial which the HIV Vaccine Trials Network organized to develop an HIV vaccine. In February 2020 the organizers halted the trial after finding no evidence of efficacy.[1][2][3]

Around December 2019 various media outlets reported that HVTN 702 could be an effective vaccine in preventing HIV.[4][5]

In 2016 various media outlets announced the start of the research.[6][7][8]

HVTN 702 was based on outcomes of the RV 144 trial.[9]

References
  1. Doughton, Sandi (3 February 2020). "'Incredibly disappointing': Fred Hutch, feds end HIV vaccine trial after data shows no benefit". The Seattle Times.
  2. "Experimental HIV vaccine regimen ineffective in preventing HIV". National Institutes of Health (NIH). 3 February 2020.
  3. Russell, Sabin (4 February 2020). "Promising HIV vaccine fails to show efficacy, trial halted". Fred Hutch.
  4. Fitzsimons, Tim (1 December 2019). "HIV vaccine in 2021? Leading experts 'optimistic' about ongoing trials". NBC News.
  5. Lee, Bruce Y. (3 December 2019). "An HIV Vaccine By 2021? Here Is What Needs To Happen". Forbes.
  6. "New HIV vaccine trial to start in South Africa". www.cbsnews.com. 28 November 2016.
  7. Galeon, Dom (29 November 2016). "An End to AIDS: New Vaccine Could Be The "Final Nail in the Coffin" for HIV". Futurism.
  8. "HIV vaccine trial begins in South Africa". BBC News. 30 November 2016.
  9. Cairns, Gus (26 July 2017). "Another HIV vaccine efficacy trial will start this year". Aidsmap.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.